Abstract:Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventions. Despite the established treatment regimen comprising surgical intervention, radiotherapy, temozolomide administration, and the exploration of emerging modalities such as immunotherapy and integration of medicine and engineering technology therapy, the efficacy of these approaches remains constrained, resulting in suboptimal prognostic outcomes. In recent years, intensive scrutiny of the inhibitory and immunosuppressive milieu within GBM has underscored the significance of cellular constituents of the GBM microenvironment and their interactions with malignant cells and neurons. Novel immune and targeted therapy strategies have emerged, offering promising avenues for advancing GBM treatment. One pivotal mechanism orchestrating immunosuppression in GBM involves the aggregation of myeloid-derived suppressor cells (MDSCs), glioma-associated macrophage/microglia (GAM), and regulatory T cells (Tregs). Among these, MDSCs, though constituting a minority (4–8%) of CD45 + cells in GBM, play a central component in fostering immune evasion and propelling tumor progression, angiogenesis, invasion, and metastasis. MDSCs deploy intricate immunosuppressive mechanisms that adapt to the dynamic tumor microenvironment (TME). Understanding the interplay between GBM and MDSCs provides a compelling basis for therapeutic interventions. This review seeks to elucidate the immune regulatory mechanisms inherent in the GBM microenvironment, explore existing therapeutic targets, and consolidate recent insights into MDSC induction and their contribution to GBM immunosuppression. Additionally, the review comprehensively surveys ongoing clinical trials and potential treatment strategies, envisioning a future where targeting MDSCs could reshape the immune landscape of GBM. Through the synergistic integration of immunotherapy with other therapeutic modalities, this approach can establish a multidisciplinary, multi-target paradigm, ultimately improving the prognosis and quality of life in patients with GBM.

Immunopathology of Extracellular Vesicles in Macrophage and Glioma Cross-Talk

Extracellular vesicles as modulators of glioblastoma progression and tumor microenvironment

Tumor-derived extracellular vesicles: how they mediate glioma immunosuppression

Immunomodulatory effects of extracellular vesicles in glioblastoma

Decoding the secret of extracellular vesicles in the immune tumor microenvironment of the glioblastoma: on the border of kingdoms

Role of Tumor-Derived Extracellular Vesicles in Glioblastoma

Roles of Extracellular Vesicles in High-Grade Gliomas: Tiny Particles with Outsized Influence

Crosstalk between extracellular vesicles and tumor-associated macrophage in the tumor microenvironment

A tale of two tumors: differential, but detrimental, effects of glioblastoma extracellular vesicles (EVs) on normal human brain cells

Hypoxic glioblastoma-cell-derived extracellular vesicles impair cGAS-STING activity in macrophages

Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives

Macrophages/Microglia in the Glioblastoma Tumor Microenvironment

Exosome‐transmitted podoplanin promotes tumor‐associated macrophage‐mediated immune tolerance in glioblastoma

GBM Immunotherapy: Macrophage Impacts

Perspectives on Microglia-Based Immune Therapies Against Glioblastoma

Interactions between microglia and glioma in tumor microenvironment

Microglia and Brain Macrophages as Drivers of Glioma Progression

Microglia and macrophages in glioblastoma: landscapes and treatment directions

Proteomics Studies on Extracellular Vesicles Derived from Glioblastoma: Where Do We Stand?

Exosomal non-coding RNAs in glioma progression: insights into tumor microenvironment dynamics and therapeutic implications

Multidimensional communication in the microenvirons of glioblastoma